2021•Materials AdvancesOpen access

Anti-GPC1-modified mesoporous silica nanoparticles as nanocarriers for combination therapy and targeting of PANC-1 cells

Bianca Martins Estevão, Edson José Comparetti, Nathália Cristina Rissi, Valtencir Zucolotto

Abstract

We present a novel therapeutic nanoplatform based on mesoporous silica nanoparticles encapsulating ferulic acid/gemcitabine and functionalized with anti-GPC1 antibodies to target human pancreatic cancer (PANC-1) cells.

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Nanocarriers, Mesoporous silica, Nanoparticle, Pancreatic cancer, Gemcitabine, Chemistry, Solid lipid nanoparticle, Nanotechnology